Enhanced Group (ENHA)
Operates performance-enhancement-permitted sports events alongside telehealth protocols and wellness supplements.
Something off on this page? Send us feedback.
Combines a performance-enhancement-permitted sports property with U.S. telehealth and supplement sales, using the Games as an audience and brand engine for Live Enhanced. Intended revenue spans media, sponsorship, licensing and consumer wellness purchases, while clinical decisions and fulfillment sit with partners.
Runs the Enhanced Games, a performance-enhancement-permitted sports-entertainment property spanning live competition, media, sponsorships and licensed consumer products. It owns the event and brand intellectual property while partners handle production and content distribution; athlete stories and audience attention are intended to support sponsorship, media-rights, merchandise and licensing revenue.
Operates Live Enhanced, a U.S.-focused direct-to-consumer platform for clinician-guided prescription protocols and non-prescription supplements. It manages the customer-facing site, retail prices, marketing and non-clinical communication, while independent clinicians determine prescriptions and partner pharmacies fulfill approved care.
Relies on outside providers for clinical services, fulfillment, manufacturing, venues, production and distribution. Prescription protocols depend on state and federal rules governing medical practice, licensure, marketing, pharmacy fulfillment and data privacy. Its dual-class share structure gives Apeiron, executive chairman Christian Angermayer's investment group, decisive influence over director elections and major corporate actions.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Mar 31, 2026Cash & short-term investments $54.6K · Total debt $0 · Total assets $26.2M · Shareholders' equity $25.1M
- Revenue
- $2.8K
- Operating income
- −$16.5M
- Net income
- −$16.4M
No dividends on record.
| Institutions | 9.46% | 12.17M shares | |
|---|---|---|---|
| 30 holders · as of Jun 30, 2026 | |||
| Strategic holders | 33.69% | 43.34M shares | |
| 1 holder · as of Sep 21, 2026 | |||
| Other | 56.85% | 73.15M shares | |
| remainder | |||
128.66M company shares as of Aug 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Apeiron Investment Group Ltd.Strategicdirector, 10 percent owner | 33.69% | 43.34M | filed Sep 21, 2026 |
Anson Funds Management LPInstitution | 1.00% | 1.29M | as of Jun 30, 2026 |
Davidson Kempner Capital Management LPInstitution | 1.00% | 1.29M | as of Jun 30, 2026 |
LMR Partners LLPInstitution | 1.00% | 1.29M | as of Jun 30, 2026 |
Citadel Advisors LLCInstitution | 1.00% | 1.29M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 17, 2026 | Apeiron Investment Group Ltd. | director, 10 percent owner: | +6,080,047 | $1.15 |
- Hims & Hers Health
Dominant DTC rival in hormones, weight loss and longevity.
- LifeMD
DTC protocol rival in TRT, hormone care and GLP-1 weight loss.
- TKO Group
Large live-sports rival for athletes, media rights and sponsors.
- WeightWatchers
Direct GLP-1 access rival in clinician-guided weight management.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Enhanced Group | $1.48 | +3.15% | $184.0M | — | — | 66,780.3 | — |
| Hims & Hers Health | $31.34 | +6.77% | $6.55B | — | 145.7 | 2.5 | +38.3% |
| LifeMD | $3.30 | +2.17% | $156.0M | — | — | 0.8 | −24.0% |
| TKO Group | $188.30 | −1.48% | $14.33B | 65.9 | 33.7 | 2.7 | +18.2% |
| WeightWatchers | $16.34 | −0.31% | $163.9M | — | — | 0.2 | — |
| Median | 65.9 | 89.7 | 1.7 | +18.2% |